New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma…